Hmo mixtures

A composition, a technology of symptoms, applied in the field of HMO mixtures

Pending Publication Date: 2022-07-15
GLYCOM AS
View PDF19 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Plus, removing dairy can have long-term nutritional consequences
Additionally, it is difficult to adhere to a low FODMAP diet for an extended period of time

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Hmo mixtures

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0090] A total of 317 male and female patients from 17 clinics were recruited for the study. Patients were eligible to participate in the study if they were: over 18 years of age at screening; had a current clinical diagnosis of IBS from a healthcare provider; and met Rome IV diagnostic criteria for IBS. Patients will be excluded from participation if they have been diagnosed with celiac disease, diverticulitis, inflammatory bowel disease or Clostridium difficile infection.

[0091] All patients underwent screening examinations at clinics where written informed consent was obtained, and inclusion and exclusion criteria were checked. After enrollment in the trial, patients filled out an electronic basic survey (Survey 1). The survey includes a number of validity questionnaires such as the Bristol Stool Type Scale (BSFS), IBS Symptom Severity Score (IBS-SSS), IBS-specific Gastrointestinal Symptom Rating Scale (GSRS-IBS) and IBS Quality of Life ( IBS-QoL). Patients also indica...

Embodiment 2

[0101] The ability of different HMOs to increase Bifidobacterium abundance in IBS feces was evaluated in a batch culture fermentation system. The following HMOs were tested: 2'-FL, LNnT, LNT, 3'-SL, 6'-SL and a mixture of 2'-FL and DFL.

[0102] Fecal samples were collected from IBS-D patients, IBS-C patients and healthy volunteers. Batch fermenters (working volume 300 ml) were set up and each was aseptically inoculated with a fecal sample, basal medium and one HMO. The temperature was maintained at 37°C (human body temperature) by a circulating water bath, and the pH was adjusted to 6.8.

[0103] The batch fermenter was run for 48 hours with samples taken at 0 hours, 8 hours and 48 hours. Samples were analyzed using:

[0104] • Use fluorescence in situ hybridization (FISH) in combination with flow cytometry (Flow-FISH) to enumerate bacterial populations. Eleven genotypic probes were used to target specific regions of 16S rRNA for major bacterial taxa of the gut microbiota...

Embodiment 3

[0107] HMO 2'-FL and LNnT were introduced into the rotary mixer at a mass ratio of 4:1. 0.25w% magnesium stearate was added to the mixer and the mixture was mixed for 10 minutes. The mixture was then coagulated in a fluid bed, filled into 5 gram stick packs, and sealed.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention relates to human milk oligosaccharides (HMOs) for use in the following, synthetic compositions comprising HMO for use in the following, and methods for prophylactically reducing the severity and / or incidence of gastrointestinal IBS symptoms in lactose intolerant IBS patients; reintroducing a lactose source into the diet of lactose intolerant IBS patients while prophylactically reducing the gastrointestinal IBS symptom severity and / or symptom incidence in IBS patients; and / or reducing the severity and / or incidence of non-gastrointestinal symptoms in lactose intolerant IBS patients.

Description

[0001] Field of Invention [0002] The present invention relates to methods, compounds and compositions for managing symptoms in lactose intolerant IBS patients. Background technique [0003] Irritable bowel syndrome (IBS) is a clinically heterogeneous functional bowel disorder with chronic symptoms such as abdominal pain, altered bowel movements, abdominal discomfort, bloating, and fatigue. Routine clinical tests on patients usually show no abnormalities, although their gut may be more sensitive to certain stimuli, such as balloon inflation tests. The global prevalence of IBS is about 10-20%, but may be higher in some countries. The etiology of IBS is unknown, but disturbances of the brain-gut axis, acute gastrointestinal infections, small intestinal bacterial overgrowth, antibiotic use, and intestinal dysbiosis are thought to be important risk factors (Kim et al., Digest. Dis. Sci. 57, 3213 (2012)). The abundance of Bifidobacterium in the stool of many patients appears to...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/702A61P2/00A61P17/02A61P25/00
CPCA61P17/02A61K31/702A61P25/00A61K2300/00A61P1/00A61P1/12
Inventor L·K·比格斯奈斯B·麦康奈尔D·塞茨伯格I·D·阿蒙森
Owner GLYCOM AS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap